NSCLC
Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is a type of epithelial lung cancer other than small-cell lung cancer (SCLC). Non-small-cell lung cancer accounts for about 85% of all lung cancers. As a class, non-small-cell lung cancers are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.
Beyond's analysis on NSCLC
- — Sacituzumab govitecan plus pembrolizumab fails to meet primary endpoints in first‑line PD‑L1‑high metastatic NSCLC, dealing a setback to the ADC‑immunotherapy combo approach
- — Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
- — Akeso initiates Phase II trial of a novel TROP2/Nectin-4 bispecific ADC combined with Ivonescimab, advancing its oncology pipeline in NSCLC
- — Kelun-Biotech’s Phase III trial shows its antibody-drug conjugate plus pembrolizumab beats chemo‑immunotherapy in PD‑L1‑negative NSCLC, potentially reshaping first‑line lung‑cancer treatment
Recent news mentioning NSCLC
- — Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
- — Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026
- — BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
- — Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
- — Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment